FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to therapeutic RNA for treating ovarian cancer. Invention discloses a pharmaceutical composition, a drug preparation and a kit containing at least one RNA which codes: (i) an amino acid sequence comprising claudin 6 (CLDN6), an immunogenic variant thereof or an immunogenic fragment of CLDN6 or an immunogenic variant thereof; (ii) an amino acid sequence comprising p53, an immunogenic version thereof or an immunogenic fragment of p53 or an immunogenic version thereof; and (iii) an amino acid sequence comprising a predominantly expressed melanoma antigen (PRAME), an immunogenic version thereof or an immunogenic fragment of PRAME or an immunogenic version thereof. In another version, each of the amino acid sequences specified in (i), (ii) or (iii) is encoded by a separate RNA.
EFFECT: administration of therapeutic RNAs to a patient suffering ovarian cancer promotes reduction of tumour size, prolongs time to disease progression and/or protects against metastasis and/or tumour recurrence.
83 cl, 29 dwg, 18 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC RNA FOR PROSTATE CANCER | 2020 |
|
RU2838161C2 |
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| DRUG CONJUGATES CONTAINING ANTI-CLAUDIN 18.2 ANTIBODIES | 2016 |
|
RU2841168C2 |
| NEW ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION | 2018 |
|
RU2805674C2 |
| FMDV-E2 FUSION PROTEINS AND USE THEREOF | 2016 |
|
RU2714428C2 |
| NGF ANTIBODIES AND RELATED METHODS | 2019 |
|
RU2838175C2 |
